Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections

Shares of Seres Therapeutics Inc. MCRB, +389.22% rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), or an infection of the colon.